教育背景

1978-1983 第二军医大学海医系 学士

1985-1988 第二军医大学第二附属医院（上海长征医院）硕士

1990-1993 澳大利亚Flinders医学中心 博士

工作经历

1983-1985 第二军医大学第二附属医院 住院医师、助教

1988-1990 第二军医大学第二附属医院 主治医师、讲师

1994-1996 澳大利亚Flinders医学中心 博士后

1996-2007 澳大利亚昆士兰医学研究所 RO，SRO，NHMRC Fellow

2002-至今 海军军医大学第二附属医院风湿免疫科 科主任

2009-2015 澳大利亚昆士兰大学 教授

2014-2018 国家科技部“973计划”项目 首席科学家

2015-至今 海军军医大学第二附属医院 内科教研室 主任

2016-2021 清华大学临床医学院 常务副院长

2016-2024 清华大学医学院 教授

2017-至今 清华-北大生命科学中心 临床研究员

2023-至今 免疫与炎症全国重点实验室 副主任

2024-至今 清华大学基础医学院 教授

研究领域

主要研究领域是自身免疫病的致病机理及创新诊断和治疗的转化研究。主要转化医学研究亮点包括：在诊断领域，率先发现不同的HLA-B27亚型在强直性脊柱炎（AS）的诊断上有重要意义，为早期和精准诊断开辟了新方向，研究被述评为该领域中的一项重大突破。在此基础上，创新性整合了国际上最大规模的AS全基因组信息（三万多人的多种族患者），开发提出并验证了基于全基因组数据的AS多基因风险评分新方法（Polygenic Risk Score）。这是国际上首次成功利用基因遗传数据构建方法模型来进行早期诊断和预测风湿免疫性疾病的研究。在治疗领域，在国际上首次使用健康人来源的异体通用型CAR-T治疗风湿免疫病并取得成功；是国际上最早揭示TH17细胞参与AS致病，促使抗IL-17抗体药物成为全球AS治疗的主流产品。在此基础上，牵头和参与了32项国际多中心II期和III期临床试验，包括全球第一项小分子靶向生物药物的III期临床试验，全球第一项IL-17A/F双抗的III期临床试验，全球第一项头对头生物类似药与原研药阿达木的III期临床试验。

科学贡献

41年来执著医学事业，临床和科研并举，在学术理论创新的主要贡献是：1、揭示强直性脊柱炎（AS）和类风湿关节炎（RA）关键发病机制，为临床诊疗带来实质性改变。首先发现了转录因子STAT3是汉族人特有的与AS发病强相关的易感基因，继而发现IL23R罕见变异体与AS发病密切相关，揭示AS的发病最终都归结到IL23R/TH17信号通路这一共同途径，率先提出了TH17细胞在AS发病中起到关键作用的理论。第一次证实了环境-遗传-免疫间存在相互作用，为剖析AS发病机制提供了新的研究方向。在RA研究中，发掘MMEL1、CTLA4 DPP4、CCR6和CDK5RAP2是汉族人RA特有的易感基因，PTPN22基因与汉族人RA没有相关性，揭示了跨人种研究的重要性。与国际同行的合作研究发现了101个RA致病位点，找到了871种候选药物靶点，极大促进了新药研发与临床应用。2. 最先发现消化道是新冠病毒感染的重要途径。在新冠肺炎爆发之初，新冠病毒的感染特性亟待研究。团队发现新冠病毒的受体ACE2和TMPRSS2不仅在肺细胞表达, 同时可在食道、回肠和结肠细胞中高表达，提出了新冠病毒除呼吸道外还存在消化道传播途径的新理论，对早期疫情防控的政策制定产生了重要影响。迄今在Cell、Nature、Nature Genetics、Lancet Rheumatology、Gut、Journal of Experimental Medicine、Proc Nat Acad Sci等主流SCI杂志发表学术论文142篇，其中14篇论文发表在风湿病顶尖杂志 Annals of the Rheumatic Diseases (IF 27.9)。研究成果以第一完成人获得“教育部科技进步奖一等奖”、“上海市科技进步奖一等奖”和“上海市医学科技奖一等奖”各一项。

荣誉奖励

2024 谈家桢临床医学奖

2024 上海市级医院临床创新奖（第一完成人）

2022 “仁心医者-上海市杰出专科医师”奖

2022 教育部科技进步奖一等奖（第一完成人）

2022 第五届“人民名医∙卓越建树”称号

2019 上海科技进步奖一等奖（第一完成人）

2019 享受国务院特殊津贴

2014 国家科技部973计划项目“首席科学家”

2013 获得上海医学科技奖一等奖（第一完成人）

2012 中央组织部高层次人才计划“国家特聘专家”

2010 入选上海市领军人才

2008 入选上海市优秀学科带头人

代表性论文（近5年）

1.Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. (2024).Allogeneic CD19-targeted CAR-T therapy in severe myositis and systemic sclerosis achieved durable remission and reversed extensive fibrotic damages. Cell. doi: 10.1016/j.cell.2024.06.027

2.Wang T, Sternes PR, Guo XK, Zhao H, Xu C, Xu H. (2024). Autoimmune diseases exhibit shared alterations in the gut microbiota. Rheumatology. 63, 856-865.

3.Liu Y, Zhang Z, Kang Z, Zhou X, Liu S, Guo S, Jin Q, Li T, Zhou L, Wu X, Wang YN, Lu L, He Y, Li F, Zhang H, Liu Y, Xu H. (2023). Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus. Ann Rheum Dis. 82, 1444-1454

4.Li JX, Wu X, Lee YH, Xu H. (2023). West Meets East in Genetics of Ankylosing Spondylitis. Int J Rheum Dis. 26, 2122-2126

5.Guo XK, Wang J, Vincent P. H, Liu J, Xu H, Hu X. (2023). Interactions between host and intestinal crypt-resided biofilms are controlled by epithelial fucosylation. Cell Rep. 42, 112754

6.Kang Z, Wang J, Meng T, Zhang H, Xu D, Gong H, Chang Z, Li Z, Cui X, Xiao J, Qureshi AI., Zhou W, Liu J, Xu H. (2023). Pericytes may facilitate SARS-CoV-2 entry into the nervous system. Journal of Bio-X Research. 6, 23-36

7.Tian H, Li T, Wang Y, Lu H, Lin L, Wu X, Xu H. (2023). The correlations between C-reactive protein and MRI-detected inflammation in patients with axial spondyloarthritis: a systematic review and meta-analysis. Clin Rheumatol. 42, 2397-2407

8.Cai B, Lu H, Ye Q, Xiao Q, Wu X, Xu H. (2023). Identification of potent target and its mechanism of action of Tripterygium wilfordii Hook F in the treatment of lupus nephritis. Int J Rheum Dis. 26, 1529-1539

9.Li Y, Li B, Wang G, Su J, Qiao Y, Ma C, Wang F, Zhu J, Li J, Zhang H, Liu K, Xu H. (2023). Engineered protein and Jakinib nanoplatform with extraordinary rheumatoid arthritis treatment. Nano Res. 16, 11197−11205

10.Wang X, Zhu L, Ying S, Liao X, Zheng J, Liu Z, Gao J, Niu M, Xu X, Zhou Z, Xu H. (2023). Increased RNA Editing Sites Revealed as Potential Novel Biomarkers for Diagnosis in Primary Sjögren’s Syndrome. J Autoimmun. 138, 103035

11.Jin Q, Liu Y, Zhang Z, We X, Chen Z, Tian H, Kang Z, Wu X, Xu H. (2023). MYC Promotes Fibroblast Osteogenesis by Regulating ALP and BMP2 to Participate in Ectopic Ossification of Ankylosing Spondylitis. Arthritis Res Ther. 25, 28

12.Chi X, Huang M, Tu H, Zhang B, Lin X, Xu H, Dong C, Hu X. (2023). Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections. Sci China Life Sci. 66, 1482-1517.

13.Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Bosch F, Vaux T, Xu H. (2023). Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomized Controlled Trials. Ann Rheum Dis. 82, 515-526

14.Huang M, Xu H. (2022). Genetic susceptibility to autoimmunity-current status and challenges. Adv Immunol. 156, 25-54

15.Ye L, Li W F, Shao J, Xu Z, Ju J, Xu H. (2022). Fighting Omicron epidemic in China: real-world big data from Fangcang Shelter Hospital during the outbreak in Shanghai 2022. J Infection. 85, 436-480

16.Wu X, Geng X, Shang Z, Wang Z, Lu H, Liu W, Xu H. (2022). Post-traumatic stress disorder in patients with rheumatic disease during the COVID-19 outbreak: a cross-sectional case-control study in China. BMJ Open. 12, e049749.

17.Wu X, Xu H, Dong C. (2022). Beyond interleukin-17-targeted therapy: Complexity of environment-genetics-immunology needs to be addressed. Chinese Med J-Peking. 135, 511-512

18.Ye L, Zhou L, Bian J, Zhao J, Li T, Wu X, Xu H. (2022). Disease activity guided stepwise tapering but not discontinuation of biologics is a feasible therapeutic strategy for patients with ankylosing spondylitis: real-world evidence. Adv Ther. 39, 1393-1402

19.Wang T, Guo X K, Xu H. (2021). Disentangling the progression of nonalcoholic fatty liver disease in the human gut microbiota. Front Microbiol. 12, 728823

20.Lu H, Wang Y, Wang X, Wu X, Zhou L, Sheng R, Tian H, Li T, Xu H. (2021). Yisaipu® provide AS patients with an economical therapeutic option while original biologicals are more advantageous in the COVID-19 epidemic situation. Front Pharmacol. 12, 692768

21.Zhou L, Li T, Wu X, Lu H, Lin L, Ye L, Yin J, Zhao J, Wang X, Bian J, Xu H. (2021). Assessment of neuropathic pain in Ankylosing Spondylitis: prevalance and characteristics. Pain Ther. 10, 1467-1479

22.Wu X, Wang G, Zhang L, Xu H. (2021). Genetics of Ankylosing Spondylitis – focusing on the ethnic difference between East Asia and Europe. Front Genet. 12, 671682

23.Li Z, Wu X, Leo PJ, Guzma L, Akkoc N, Breban M, MacFarlane G, Mahmoudi M,Marzo-Ortega H, Anderson L, Wheeler L, Chou CT, Harrison AA, Stebbings S, Jones GT, Bang SO, Wang G, Song J, Lin L, Li M, Wei JZZ, Martin NG, Wright MJ, Lee M, Wang Y, Zhan J, Zhang JS, Wang XB, Jin ZB, Weisman MH, Gensler LS, Ward MM, Rahbar MH, Diekman L, Kim T, Reveille JD, Wordsworth PB, Xu H, Brown MA. (2021). Polygenic risk scores have high diagnostic capacity in ankylosing spondylitis. Ann Rheum Dis. 80, 1168-1174

24.Brown MA, Xu H, Li Z. (2020). Genetics and the axial spondyloarthritis spectrum. Rheumatology. 59, iv58-iv66

25.Wu X, Zheng H, wang C, Xu S, Gao G, Li M, Wang Z, Jiang C, Dou Z, Xiao Y, Xie K, Wang S, Xu H. (2020). A novel privacy-preserving federated genome-wide association study framework and its application in identifying potential risk variants in ankylosing spondylitis. Brief Bioinfirm. 22, bbaa090

26.Zhang H, Kang Z, Gong H, Xu D, Wang J, Li ZX, Li ZF, Cui XG, Xiao JR, Zhan J, Meng T, Zhou W, Liu JM, Xu H. (2020). Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 69, 1010-1018

27.Wang G, Kim TH, Li ZX, Cortes.A, Kim K, Bang SY, Leo P, Brown MA, Xu H. (2020). MHC associations of ankylosing spondylitis in East Asians are complex and involve non-HLA-B27 HLA contributions. Arthritis Res Ther. 22, 74

28.Shi XY, Wang G, Li T, Li Z, Leo P, Liu Z, Wu G, Zhu H, Zhang Y, Li D, Gao L, Yang L, Wang W, Liao J, Wang J, Zhou S, Wang H, Li X, Gao J, Zhang L, Shu X, Li D, Li Y, Chen C, Zhang X, Reutens D, Bartlett P, Brown MA, Zou LP, Xu H. (2020). Identification of susceptibility variants to benign childhood epilepsy with centro-temporal spikes (BECTS) in Chinese Han population. EBioMedicine. 57, 102840

29.Liu Y, Wu X, Ye L, Xu H. (2020). Successful treatment of a patient with kasabach–merritt syndrome and multiple giant hepatic hemangiomas. J Int Med Res. 48, 030006051989835

30.Xu H, Yin J. (2020). HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis. Best Pract Res CL RH. 33, 101499

31.Li T, Liu Y, Sheng R, Yin J, Wu X, Xu H. (2020). Correlation between chronic pain acceptance and clinical variables in ankylosing spondylitis and its prediction role for biologics treatment. Front Med (Lausanne). 7, 17

32.Yin J, Sternes P, Wang M, Song J, Morrison M, Li T, Zhou L, Wu X, He F, Zhu J, Brown MA, Xu H. (2020). Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 79, 132-140

33.Zhang W, Zhang H, Liu S, Xia F, Kang Z , Zhang Y, Liu Y, Xiao H, Chen L , Huang C, Shen N, Xu H, Li F. (2019). Excessive CD11c(+)T bet(+) B cells promote aberrant T-FH differentiation and affinity-based germinal center selection in lupus. P Natl Acad Sci USA. 116, 18550-18560

34.Wu X, Lu H, Xu H. (2019). Andersson lesion in ankylosing spondylitis misdiagnosed as spinal tuberculosis: two cases. Int J Clin Exp Med. 12, 14001-14004

35.Li T, Zhou L, Zhao H, Song J, Wang X, Liu S, Xu H. (2019). Fatigue in ankylosing spondylitis is associated with the psychological factors and brain gray matter. Front Med (Lausanne). 6, 271

36.Xu H, Li Z, Wu J, Xing Q, Shi G, Li J, Liu X, Wu L, Li X, Tan W, He D, Bi L, Li H, Xiao Z, Shuai Z, Li X, Wang Y, Luo L, Zheng Y, Xiao W, Wu X, Zhou L, Li T, Qian L, Zhou H, Lu S, Zheng S, Xiong Y, Wang X, Wang Y, Wu X. (2019). IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomized, double-blind, phase 3 equivalence trial. Lancet Rheum. 1, e35–43

37.Liu Y, Zhang Z, Jin Q, Liu Y, Kang Z, Huo Y, He Z, Feng X, Yin J, Wu X, Wang H, Xu H. (2019). Hyperprolactinemia is associated with a high prevalence of serum autoantibodies, high levels of inflammatory cytokines and an abnormal distribution of peripheral B cell subsets. Endocrine. 64, 648-656

38.Khanniche A, Zhou L, Jiang B, Song J, Jin Y, Yin J, Wang S, Ji P, Shen H, Wang Y, Xu H. (2019). Restored and enhanced memory T cell immunity in rheumatoid arthritis after TNFα blocker treatment. Front Immunol. 10, 887

39.Wu X, Sheng X, Sheng R, Lu H, Xu H. (2019). Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis. Frontiers of Medicine. 13, 411-419

Complete list of publications: https://www.scopus.com/authid/detail.uri?authorId=15078044400

https://www.webofscience.com/wos/author/record/AAB-2902-2021